La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Actinogen Medical Crescita futura

Future criteri di controllo 2/6

Si prevede che Actinogen Medical aumenterà gli utili e i ricavi rispettivamente del 3.3% e 83.2% all'anno, mentre si prevede che l'EPS crescerà del 28% all'anno.

Informazioni chiave

3.3%

Tasso di crescita degli utili

28.0%

Tasso di crescita dell'EPS

Biotechs crescita degli utili	14.4%
Tasso di crescita dei ricavi	83.2%
Rendimento futuro del capitale proprio	n/a
Copertura analitica	Low
Ultimo aggiornamento	22 Aug 2024

Aggiornamenti recenti sulla crescita futura

Recent updates

Here's Why We're Not Too Worried About Actinogen Medical's (ASX:ACW) Cash Burn Situation

Aug 09

Here's Why We're Not Too Worried About Actinogen Medical's (ASX:ACW) Cash Burn Situation

Apr 07

We're Not Worried About Actinogen Medical's (ASX:ACW) Cash Burn

Oct 24

Actinogen Medical (ASX:ACW) Is In A Strong Position To Grow Its Business

Jul 11

We're Interested To See How Actinogen Medical (ASX:ACW) Uses Its Cash Hoard To Grow

Mar 27

How Does Actinogen Medical's (ASX:ACW) CEO Pay Compare With Company Performance?

Jan 07

Previsioni di crescita degli utili e dei ricavi

ASX:ACW - Stime future degli analisti e dati finanziari passati (AUD Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
6/30/2025	7,601	-14	-9	N/A	1
6/30/2024	7,907	-15	-17	N/A	1
12/31/2023	5	-15	-13	-13	N/A
9/30/2023	5	-13	-11	-11	N/A
6/30/2023	5	-11	-9	-9	N/A
3/31/2023	5	-11	-9	-9	N/A
12/31/2022	5	-11	-9	-9	N/A
9/30/2022	4	-10	-9	-9	N/A
6/30/2022	4	-9	-10	-10	N/A
3/31/2022	3	-8	-8	-8	N/A
12/31/2021	2	-7	-6	-6	N/A
9/30/2021	2	-6	-4	-4	N/A
6/30/2021	2	-4	-2	-2	N/A
3/31/2021	2	-4	-2	-2	N/A
12/31/2020	3	-4	-2	-2	N/A
9/30/2020	3	-4	-3	-3	N/A
6/30/2020	4	-5	-3	-3	N/A
3/31/2020	5	-6	-5	-5	N/A
12/31/2019	6	-7	-7	-7	N/A
9/30/2019	5	-8	-9	-9	N/A
6/30/2019	5	-10	-10	-10	N/A
3/31/2019	4	-10	-10	-10	N/A
12/31/2018	3	-10	-9	-9	N/A
9/30/2018	3	-8	-8	-8	N/A
6/30/2018	3	-6	-8	-8	N/A
3/31/2018	2	-6	-6	-6	N/A
12/31/2017	2	-5	-4	-4	N/A
9/30/2017	1	-4	N/A	-3	N/A
6/30/2017	1	-3	N/A	-1	N/A
3/31/2017	2	-4	N/A	-2	N/A
12/31/2016	3	-4	N/A	-2	N/A
9/30/2016	3	-4	N/A	-4	N/A
6/30/2016	4	-4	N/A	-5	N/A
3/31/2016	3	-5	N/A	-5	N/A
12/31/2015	1	-5	N/A	-5	N/A
9/30/2015	1	-5	N/A	-4	N/A
6/30/2015	0	-5	N/A	-4	N/A
3/31/2015	0	-3	N/A	-2	N/A
12/31/2014	0	-2	N/A	-1	N/A
9/30/2014	0	-1	N/A	-1	N/A
6/30/2014	0	0	N/A	0	N/A
3/31/2014	0	0	N/A	0	N/A
12/31/2013	0	0	N/A	0	N/A
9/30/2013	0	0	N/A	0	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che ACW rimarrà non redditizia nei prossimi 3 anni.

Guadagni vs Mercato: Si prevede che ACW rimarrà non redditizia nei prossimi 3 anni.

Guadagni ad alta crescita: Si prevede che ACW rimarrà non redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di ACW ( 24% all'anno) crescerà più rapidamente del mercato Australian ( 5.3% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di ACW ( 24% all'anno) crescerà più rapidamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di ACW è previsto essere elevato tra 3 anni

Actinogen Medical Crescita futura

Future criteri di controllo 2/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Consensus revenue estimates increase by 11%

Price target increased to AU$0.15

Recent updates

Actinogen Medical Limited as Announces Achievement of Clinically and Statically Significant Superiority of Xanamem over Placebo on Depression in Xanacidd Phase 2A Trial

New minor risk - Market cap size

Actinogen Medical Limited Announces the Peer-Reviewed Publication of its Phase 2a Biomarker

New major risk - Revenue and earnings growth

Actinogen Medical Limited has filed a Follow-on Equity Offering in the amount of AUD 5 million.

Is Actinogen Medical (ASX:ACW) In A Good Position To Invest In Growth?

Actinogen Medical Limited Announces First Patient Treated in XanaMIA Phase 2b Alzheimer's Disease Trial

New major risk - Share price stability

Actinogen Medical Limited Announces Enrolment in the XanaCIDD Phase 2A Proof-Of-Concept Trial

Is Actinogen Medical (ASX:ACW) In A Good Position To Invest In Growth?

Actinogen Medical Limited Announces CFO Changes

AActinogen Medical Limited to Present Progress on Phase 2 Trials At the Bio Investor Forum, San Francisco and Clinical Trials on Alzheimer's Disease Conference, Boston

New minor risk - Share price stability

Actinogen Medical Limited Announces Optimization of XanaMIA Phase 2b Trial in Patients with Mild-to-Moderate Alzheimer's Disease to Reduce Cost and Time to Initial Results

New minor risk - Shareholder dilution

Actinogen Medical Limited, Annual General Meeting, Nov 08, 2023

New minor risk - Financial data availability

Is Actinogen Medical (ASX:ACW) In A Good Position To Invest In Growth?

New major risk - Financial position

Actinogen Medical Limited to Present Progress on Cognitive Impairment in Depression and Alzheimer's Disease Phase 2 Trials at the BIO International Convention

We Think Actinogen Medical (ASX:ACW) Can Afford To Drive Business Growth

Consensus revenue estimates increase by 11%

Actinogen Medical Limited Announces Executive Changes

Actinogen Medical Ltd Announces Receipt of Agreement from US Food and Drug Administration Agrees to Six-Month Phase 2b Alzheimers Disease Trial

Actinogen Medical Limited Announces First Patient Treated in Depression and Cognitive Impairment Phase 2 Clinical Trial

Actinogen Medical Limited Announces First Patient Treated in XanaCIDD Phase 2 Depression Trial

We're Hopeful That Actinogen Medical (ASX:ACW) Will Use Its Cash Wisely

Price target increased to AU$0.15

Independent Non-Executive Director exercised options to buy AU$180k worth of stock.

MD, CEO & Director recently bought AU$94k worth of stock

Actinogen Medical Limited Announces Positive Alzheimers Disease Clinical Results

Actinogen Medical Limited, Annual General Meeting, Nov 16, 2022

Here's Why We're Not Too Worried About Actinogen Medical's (ASX:ACW) Cash Burn Situation

Actinogen Medical Limited Announces Phase 2 Trials in Alzheimer's Disease and Depression

Actinogen Medical Limited Announces Phase 2 Trial Designs for AD & MDD

MD, CEO & Director recently bought AU$128k worth of stock

Actinogen Medical Limited Announces Positive XanaMIA Results for Xanamem

Here's Why We're Not Too Worried About Actinogen Medical's (ASX:ACW) Cash Burn Situation

Actinogen Medical Limited Announces Executive Changes

Actinogen Medical Expects Top-Line Results for the XanaMIA Part A Trial to Be Available in April 1

Actinogen Medical Announces Enrolment Reach in the XanaMIA Part A Trial of 105 Participants

We're Not Worried About Actinogen Medical's (ASX:ACW) Cash Burn

Actinogen Medical Limited Completes Global Patent Family Grant

Actinogen Medical Limited Announces First Patient Enrolled in XanaMIA Trial

Actinogen Medical (ASX:ACW) Is In A Strong Position To Grow Its Business

Actinogen Receives Positive Pre-IND FDA Advice for FXS

Actinogen Medical Receives Ethics Committee Approval for XanaMIA study

We're Interested To See How Actinogen Medical (ASX:ACW) Uses Its Cash Hoard To Grow

Actinogen Medical Limited Appoints Steven Gourlay as CEO

MD, CEO & Director John Ketelbey has left the company

MD, CEO & Director John Ketelbey has left the company

Actinogen Medical Limited Announces Executive Changes

Actinogen Medical Wins FDA Actinogen's Drug Xanamem Rare Paediatric Disease Designation for the Treatment of Fragile X Syndrome

How Does Actinogen Medical's (ASX:ACW) CEO Pay Compare With Company Performance?

Actinogen Medical Limited Announces Two New Clinical Trials

Actinogen Medical Limited Appoints Jeff Carter as Chief Financial Officer

Previsioni di crescita degli utili e dei ricavi

Previsioni di crescita futura degli analisti

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

Scoprire le aziende in crescita